Evidence map›Paper›PMID 41597583›Full record

ReviewMicroorganisms2025

Microbiome and Skin Health: A Systematic Review of Nutraceutical Interventions, Disease Severity, Inflammation, and Gut Microbiota.

Alia Ashkanani, Ghalya Ashkanani, Mahmoud Yousef, Mlaak Rob, Maha Al-Marri, Nesha Naseem, Sa'ad Laws, Ali Chaari

Registry-linked trialAbstract readReview
In one paragraph

Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07539129 (A Randomized Controlled Trial Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07539129 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized Controlled Trial Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation (Interleukin-6) Levels

TypeinterventionalSponsorFoundation University IslamabadRan2026 to 2027Enrolled64ConditionsAcne VulgarisArmsProbiotics, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alia AshkananiWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.
Ghalya AshkananiWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.
Mahmoud YousefWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.ORCID 0009-0008-0944-9644
Mlaak RobWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.ORCID 0009-0004-8458-2382
Maha Al-MarriWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.
Nesha NaseemWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.
Sa'ad LawsWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.ORCID 0000-0001-9566-5459
Ali ChaariWeill Cornell Medicine Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.ORCID 0000-0003-0171-143X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin disorders are a major global cause of morbidities, and increasing evidence links several to gut microbiome dysregulation. Because of this the bidirectional gut-skin axis, nutraceuticals have been proposed as therapeutic adjuncts, but their clinical effects across skin conditions remain unclear. To understand how pro/pre/synbiotics can affect health, we conducted a systematic review to investigate disease severity indices, inflammatory and immunological markers, quality of life, and changes in gut microbiota composition. PubMed, Embase, and Web of Science were utilized to identify relevant randomized clinical trials. Selected articles were pre-piloted for in-depth analysis and data extraction. We included 60 randomized controlled trials involving human participants with 5 dermatological conditions, including atopic dermatitis, psoriasis, acne vulgaris, chronic urticaria, and melasma, treated with probiotics, prebiotics, or synbiotics. Risk of bias was generally low across trials, with some having concerns. The SCORAD of the treated group was substantially lower than that of the placebo group in 30 of the 47 trials on atopic dermatitis. Inflammatory markers showed a range of results; some showed significant changes, while others produced contradictory results. Five trials that examined atopic dermatitis and psoriasis independently showed a significant improvement in Quality of Life. The PASI score was considerably lower in psoriasis in three of the five RCTs. Acne vulgaris, melasma, and chronic urticaria were not well documented. Major limitations included heterogeneity in interventions and outcomes, small sample sizes, and inconsistent reporting of microbiome analyses. Nutraceuticals show potential as additional treatments, but further, large scale studies are required.

Indexed as

acne vulgarisatopic dermatitischronic urticariadysbiosisgut-skin axismelasmamicrobiome modulationnutraceuticalsprebioticsprobioticspsoriasisskin diseasessynbioticssystematic review

Identifiers

PMID41597583
PMCPMC12844480

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.